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Background: Some patients are at high risk of aneurysm recurrence after endovascular 
treatment: patients with large aneurysms (PRET-1) or with aneurysms that have 
previously recurred after coiling (PRET-2). We aimed to establish whether the use of 
hydrogel coils improved efficacy outcomes as compared with bare platinum coils. 
Methods: PRET was an investigator-led, pragmatic, multicenter, parallel, randomized 
(1:1) trial. Randomized allocation was performed separately for PRET-1 and PRET-2 
patients, using a web-based platform ensuring concealed allocation. The primary 
outcome was a composite of a residual/recurrent aneurysm, adjudicated by a blinded 
core lab, or retreatment, intracranial bleeding, or mass effect during the 18 month 
follow-up period. Secondary outcomes included adverse events, mortality and morbidity 
(mRS>2). The hypothesis was that hydrogel would decrease the primary outcome from 
50% to 30% at 18 months, necessitating 125 patients per group (500 for PRET-1 and 
PRET-2). 
Results: The trial was stopped once 250 PRET-1 and 197 PRET-2 patients had been 
recruited, because of slow accrual. A poor outcome occurred in 55/124 (44.4% (35·5%-
53·2%)) PRET-1 patients allocated to platinum, compared to 63/120 (52·5% (43·4%-
61·6%)) patients allocated to hydrogel (OR: 1·387 (0·838-2·295); P=0·20) and in 47/96 
(49·0% (38·8%-59·1%)) PRET-2 patients allocated to platinum, compared to 40/95 
(42·1% (32·0%-52·2%)) allocated to hydrogel (OR: 0·959 (0·428-1·342); P=0·34). Adverse 
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events and morbidity were similar. There were 16 deaths (3·6%; 3 platinum; 13 
hydrogel; P=0·011). 
Conclusion:  Coiling of large and recurrent aneurysms is safe but often poorly effective 
according to angiographic results. Hydrogel coiling was not shown to be better than 
platinum.  
 
RESEARCH IN CONTEXT 
Evidence before this study 
Endovascular coiling has revolutionized the management of intracranial aneurysms. One 
drawback of coiling is the occurrence of residual or recurrent aneurysms at follow-up 
angiography in 20-30% of patients. Hydrogel coils have been introduced in 2002 in an attempt 
to improve the stability of aneurysm occlusion, but evidence remains inconclusive. A 
randomized trial comparing hydrogel and platinum coiling published in 2011 failed to confirm its 
primary hypothesis in favor of hydrogel coils. A recent systematic review of randomized trials 
concluded in a reduction of residual aneurysms after hydrogel, but results were barely 
significant. Results in large aneurysms (>10mm) were similar. Recurrent aneurysms after 
platinum coiling are at high risk of re-recurring when re-treated, but these patients were 
excluded from all published randomized trials.  
Added value of this study 
The patient prone to recurrences after endovascular treatment (PRET) study was designed to 
offer an alternative to platinum coiling to patients with large (≥ 10mm) or recurrent aneurysms 
after coiling previously shown to be at high risk of recurrence, and usually excluded from clinical 
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trials. The PRET study showed that coiling of large and recurrent aneurysms is safe but often 
poorly effective according to angiographic results. Hydrogel coiling was not shown to be better 
than platinum.  
Implications of all the available evidence 
How patients with large or recurrent aneurysms should be managed (with endovascular 
innovations such as stenting or flow diversion, or with surgical clipping) remains an open 







Endovascular coiling has revolutionized the management of intracranial aneurysms.1,2 
Coiling has been shown safe and effective in the treatment of ruptured aneurysms, as 
compared to surgical clipping.3 Coiling is also frequently used to preventively treat 
unruptured aneurysms, even though it has never been proved superior to clipping or to 
observation.4,5 One drawback of coiling is the occurrence of residual or recurrent 
aneurysms at follow-up angiography in 20-30% of patients.6-8 The impact of recurrent 
aneurysms on long term clinical outcomes remains unclear. They have infrequently been 
associated with subarachnoid hemorrhage, in the range of 0·1-1% per year.7,9 
Nevertheless, concerns for recurrences have a number of clinical consequences, such as 
routine angiographic surveillance of nearly all patients, retreatments in 5%-15%, and 
more recently the emergence and growing utilization of potentially more effective, but 
also potentially more risky alternatives, such as stenting or flow diversion.10-13 
Hydrogel coils have been introduced in 2002 in an attempt to improve the stability of 
aneurysm occlusion while preserving the safety of coiling, but evidence remains 
inconclusive. A randomized trial comparing hydrogel and platinum coiling published in 
2011 failed to confirm its primary composite endpoint in favor of hydrogel coils, but 
demonstrated improved core-laboratory adjudicated angiographic outcomes overall and 
in pre-specified subgroups of medium (5·0-9·mm) and ruptured aneurysms. 11,14There 
was no difference in retreatment rates.  A recent systematic review of randomized trials 
concluded in a reduction of residual aneurysms after hydrogel as compared with 
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platinum coiling, but results were barely significant.15 Recurrent aneurysms after 
platinum coiling are at high risk of re-recurring when re-treated, but these patients were 
excluded from all published randomized trials.8,14,16-18 
The patient prone to recurrences after endovascular treatment (PRET) study was 
designed in 2007 to offer an alternative to platinum coiling to patients previously shown 
to be at high risk of recurrence: patients with large (≥ 10mm) or recurrent aneurysms 
after coiling. The trial protocol was published in 2008.19 We aimed to establish whether 
the use of hydrogel coils improved efficacy outcomes compared with bare platinum 
coils, without increasing procedural risks. Similar peri-procedural (30 days) outcomes 
were reported for hydrogel and platinum coiling.20 We now report the primary outcome 
of the trial: The primary hypothesis was that the use of hydrogel coils would decrease 
the proportion of residual or recurrent aneurysms from 50% to 30% (range from 50-40% 







PRET was an investigator-led, pragmatic, multicenter, international, randomized (1:1), 
controlled trial comparing a policy of using hydrogel versus bare platinum coils in the 
endovascular treatment of intracranial aneurysms. There were 25 participating clinical 
sites from 6 countries (United States, Canada, United Kingdom, France, Chile, Japan). 
The ClinicalTrials.gov registration number from the US National Institutes of Health is 
NCT00626912. All trial sites had local institutional review board approval. All patients 
(or legal representatives) signed a standardized informed consent form. 
During the course of the trial, no change in methods or protocol occurred, but multiple 
different types of hydrogel coils were being manufactured, approved and used.  
Participants 
Eligible patients, with an intracranial aneurysm requiring endovascular treatment, fell 
into 1 of 2 groups: PRET-1, with a large aneurysm (longest dimension ≥10 mm, including 
any thrombosed portion), never treated; PRET-2, with an aneurysm of any size, 
presenting with a post-coiling recurrence requiring retreatment. There were few 
selection criteria: the patient was 18 years of age or older; life expectancy was >2 years; 
the aneurysm could be ruptured (World Federation of Neurological Societies grade < 4) 
or unruptured; anatomy was such that endovascular treatment was considered possible 
with both types of coils; the endovascular operator was satisfied with using either type 
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of coil, but no other type; and the patient or authorized representative had been given 
fully informed consent and had signed the consent form. Patients were not eligible if 
they met any of the following criteria: the presence of other aneurysms requiring 
treatment during the same session; the presence of an associated cerebral 
arteriovenous malformation; the primary intent of the procedure being parent vessel 
occlusion without simultaneous endovascular coiling of the aneurysm; and any absolute 
contraindication to endovascular treatment, angiography, or anesthesia. 
Trial sites were tertiary centers experienced in the endovascular treatment of 
aneurysms using both platinum coils (at least 100 patients treated prior to enrollment) 
and hydrogel-coated coils (at least 10 patients previously treated). 
Interventions 
Standard local endovascular procedures were followed. Any locally approved bare 
platinum coil with controlled detachment was permitted, as were any assist devices 
believed necessary by the operator, provided they had local regulatory approval, 
excluding flow diverters, irrespective of intended use indicated at randomization. 
Antiplatelet and anticoagulation regimens were left to individual operator judgment, 
according to the clinical practice at each site. When treatment allocation was to 
“platinum,” types of coils other than bare platinum were forbidden. When treatment 
allocation was to “hydrogel,” any coil of the hydrogel family was allowed but any bare 
platinum coil could also be used if the operator believed it was in the patient’s best 
interest. Recommendations concerning hydrogel coil use pertaining to type, size, and 
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sequence of introduction were issued but not enforced. No minimum percentage of 
hydrogel coils was prescribed; the protocol required “the substitution, as far as possible, 
of platinum by hydrogel coils, the operator always being allowed to use the coils he/she 
believes is appropriate at any time during the procedure.”15 ‘Successful hydrogel coiling’ 
was predefined as 2/3 of total coil length being hydrogel coils, to be used for 
explanatory analyses only. Other technical considerations such as preparing or steaming 
of hydrogel coils and the type of bare platinum coil were left entirely to the operator’s 
discretion. The goal of the procedure was to occlude the aneurysm as completely as 
possible, keeping the risks of the procedure as low as possible.15  
Outcomes 
The primary outcome of the trial was the proportion of patients with a recurrence, 
defined as 1) major angiographic recurrence of the lesion or the presence of a residual 
aneurysm at last angiographic follow-up, as determined by the core laboratory, blinded 
to treatment allocation; 2) retreatment of the same aneurysm by endovascular or 
surgical means during the 18-month follow-up period; 3) an intracranial bleeding 
episode, or the occurrence or progression of a mass effect in relation to the treated 
aneurysm during the follow-up period, as determined by the blinded Adverse Event 
Committee. Immediate treatment failures, and missing follow-up angiographic data 
because of treatment or aneurysm-related deaths or poor clinical outcomes (mRS>2) 
were treated as primary outcome events. 
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Secondary outcomes included safety data, mortality and morbidity, and adverse events, 
defined as an event of any severity being possibly or probably related to the disease or 
the treatment and happening at any time during the 18-month follow-up period. The 
independent Adverse Event Committee was responsible for the attribution of secondary 
outcome events. The protocol prespecified that morbidity would be defined per patient, 
according to the mRS score (mRS >2). Adverse events reports and individual case report 
forms were cross-checked to determine the secondary safety endpoint for each patient.  
Periprocedure safety endpoints were reported. Delayed safety outcomes were 
categorized as: subarachnoid hemorrhage; progressive mass effect; stroke; transient 
ischemic events; inflammatory complications potentially related to coils; non-
neurologic; retreatment-related; others. 
Number of patients 
According to a two-sided log rank test, 250 subjects (125 in each group) were judged 
necessary to achieve 80% power at a 0.0250 significance level to detect a difference of 
0·20 (between 0·30 and 0·50) in primary outcome events between the intervention and 
control groups, for PRET-1 and PRET-2 patients separately, assuming a 10% proportion 
of patients lost during follow up.19  
Randomization 
Randomized allocation (1:1) was through the Web-based PRET application package 
(MediSciNet, Stockholm, Sweden), ensuring that allocation was concealed before the 
decision to include a patient. From the moment of randomization, the patient was in the 
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trial and accounted for in the analysis (intention-to treat). PRET-1 and PRET-2 patient 
groups were randomized separately; treatment groups were matched according to the 
following minimization criteria: rupture status (yes, no); if the aneurysm was 
unruptured, planned use of an adjunct device (yes, no).  
Masking and trial monitoring 
Masking of the treatment teams was not possible. Patients were masked unless they 
specifically requested otherwise. The Adverse Event Committee and the Data Safety and 
Monitoring Committees (DSMC), working independently from the Steering Committee, 
had access to masked data, but the DSMC could unmask groups whenever members 
thought that unmasking was mandatory to protect the safety of participants; the need 
for unblinding did not arise during the conduct of the trial. Monitoring of trial data 
quality was web-based and carried out by periodic review of data stored in the 
database.  
Data collection 
Data capture and management were held independent of the sponsor and funder on 
the secure servers of MedSciNet, ISO27000 and SAS-70 compliant. Details of data 
collection were given elsewhere.20 Briefly, following registration, intervention and 
discharge data collection, clinical follow-up data were recorded at 1, 6 and 18 months, 
and angiographic follow-up imaging was carried out at 6 months and 18 months. 
Adverse events and additional interventions on the target aneurysm were reported at 
any time during the trial. When an additional intervention was planned following the 18 
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month angiographic follow-up, the form allowed the recording of this event (YES/NO 
check-box), although some sites also chose to complete an additional intervention form 
as well. Anonymized angiographic (catheter or non-invasive, including additional 
procedures) were sent in batches to the independent core laboratory (lead P.M. White, 
Stroke Research Group, Institute of Neuroscience and Newcastle University Institute of 
Neuroscience, Newcastle upon Tyne, UK) for adjudication of location, dimensions and 
occlusion state of the aneurysm. The core laboratory was masked to treatment 
allocation and treatment received; assessment of occlusion state was according to the 
revised three-point Montreal scale, and evolution (stable, better, worse) as well of 
occurrence of a major recurrence, defined as sufficiently large to technically allow 
placements of further coils, was recorded.21  
Statistical methods 
All analyses were performed by the trial statistician according to the published trial 
protocol.19 Analyses were intent-to- treat. The primary outcome was studied using odd 
ratios with 95% confidence intervals (platinum coiling as reference). Multiple sensitivity 
analyses were performed for missing values. Exploratory stratified analyses were done, 
adjusting for rupture status, location, aneurysm size and the use of adjunct devices. The 
median packing density was compared between Hydrogel and platinum with Mann-
Whitney U tests. Packing density is the volume of inserted coils divided by the aneurysm 
volume. Coil volume (V) was calculated using the formula V = π(c/2)2L where c is coil 
caliber and L is coil length for coils entered in the procedural CRFs. Aneurysm volumes 
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(VA) were determined using a simple mathematical model VA = 4/3 π ab (a+b)/2, where a 
and b are half the long and short axes of the aneurysm, as entered on the CRFs).  The 
number of deaths was compared with a Fisher’s exact test. To evaluate the possibility of 
different results for PRET-1 and PRET-2, we stratified descriptive and safety analyses by 
groups. All analyses were made with SPSS, Version 23 (IBM, Armonk, New York) by using 
a significance level of 5%. 
Role of the funding source 
The trial was sponsored by the Centre Hospitalier de l’Université de Montréal and 
funded by MicroVention Terumo Incorporated. The sponsor and funder had no part in 
study design, data collection, analysis, or reporting and had no direct or indirect access 
to the data or source documents. The Steering Committee bears the sole responsibility 
for all aspects of the trial. 
RESULTS 
Patients were recruited between June 2007 and January 2014. On December 13, 2013, 
the Steering Committee decided to stop recruitment after the target number of patients 
(n= 250) had been recruited in PRET-1, but before reaching the target number of 
patients for PRET-2, because the trial was already 2 years behind schedule, recruitment 
rates were decreasing and provisions had to be made to cover compensations to 
participating sites for the 18-month follow-up data. For each group, the numbers of 
participants who were randomly assigned, received intended treatment, and were 
analyzed for the primary outcome are illustrated in the flow diagram (Figure 1). The 
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number of screened patients cannot be provided because eligibility logs were not 
required per protocol.  A total of 447 patients were recruited by 25 centers in 6 
countries, 250 in PRET-1 and 197 in PRET-2. 
The baseline patient and aneurysm characteristics are shown in Table 1. Groups were 
comparable. 
Three patients (0·7%; 2 PRET-1 and 1 PRET-2; all 3 hydrogel) were withdrawn before any 
treatment was attempted (1 protocol violation [World Federation of Neurological 
Societies 4 after SAH]), 1 PRET-1 aneurysm judged untreatable, 1 patient in PRET-2 in 
whom no true recurrence was found). There was 1 cross-over from hydrogel to 
platinum, and 1 cross-over from platinum to hydrogel, included in the intent-to-treat 
analyses.  
There were 9 patients (2·0%; 2 platinum; 7 hydrogel) for whom the primary outcome 
could not be attributed because consent was withdrawn (2 hydrogel), because of lack of 
follow-up from unrelated mortality (1 hydrogel), or patients were lost at follow-up (2 
platinum; 4 hydrogel). (Details provided in Online Table 1). 
For 24 patients (5·4%; 11 platinum; 13 hydrogel), the 18-month follow-up angiogram 
was not available and the primary outcome was adjudicated using the 6-month follow-
up angiogram. For 17 patients (3·8%), the primary outcome was determined on the 
basis of a treatment failure and no further angiographic follow-up (no coil deployed: 3 
platinum; 5 hydrogel; residual aneurysm: 4 platinum; 5 hydrogel). 
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The primary outcome, available for 435/447 patients (97·3%) was reached in 102/220 
(46·4%) and 103/215 (47·9%) patients of the platinum and hydrogel groups respectively 
(OR: 1·064 (0·730; 1·550; P=0·747). Each component of the composite primary outcome 
is detailed for PRET-1 and PRET-2 separately in table 2.  Results for predetermined 
subgroups (unruptured aneurysms; carotid aneurysms; use of stents; size and location) 
are detailed in Tables 3-5 and in the forest plots (Figure 2).  
A poor outcome occurred in 55/124 (44·4% (35·5%-53·2%)) PRET-1 patients with large 
aneurysms allocated to platinum, compared to 63/120 (52·5% (43·4%-61·6%)) patients 
allocated to hydrogel (OR: 1·387; [0·838; 2·295]; P=0·204). 
In PRET-2 patients that already presented with a recurrence, a poor outcome occurred 
in 47/96 (49·0%; 38·8%-59·1%) and 40/95 (42·1%; 32·0%-52·2%) patients allocated 
platinum and hydrogel respectively (OR: 0·959; [0·428; 1·342]; P=0·342). 
The angiographic outcome (residual or recurrent aneurysms) accounted for most 
primary outcome events (92·2%); the clinical components (SAH, mass effect, related-
morbidity or mortality; n=4 each) accounted for 16/205 or 7·8% of primary outcome 
events. Forty-six patients (10·4%; 21 platinum; 25 hydrogel) were retreated during the 
18 month follow-up, but 34 other retreatments (7·7%; 19 platinum; 15 hydrogel) were 
planned. 
Four different sensitivity analyses (excluding patients with no angiographic follow-up 
study from analyses (total n = 426); counting the 9 patients with no primary outcome as 
good; or as poor outcomes (n=444); including the 3 patients withdrawn before 
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treatment as treatment failures (n=447)) did not change results (Online Table 2). 
Repeating all analyses, adjusting for aneurysm location, dimension of the long or short 
axis, width of the neck, rupture status, or use of stents, did not change results. 
Exploratory analyses, including only patients in whom the target length of hydrogel coils 
was met (103/120 (85·8%) in PRET-1 and 88/95 (92·6%) in PRET-2), and repeating all 
sensitivity analyses, did not show any significant difference between platinum and 
hydrogel (P > 0·08 in all cases).  There was a significant difference between PRET-1 and 
PRET-2 patients when patients lost, withdrawn, or without a primary outcome and when 
the hydrogel target was not met were excluded (n=395) (P=0·025) (Online Table 3). 
The median packing density of hydrogel-treated aneurysms (50·9%) was significantly 
higher (P< 0·001) than platinum (22·0%). Patients reaching the primary outcome had a 
significantly lower packing density (P < 0·001) than patients without a recurrence, 
whether platinum or hydrogel was used (Table 6). 
The peri-procedural morbidity, mortality and adverse events (up to 1 month) have 
previously been published.20 Twenty-seven additional adverse events (14 platinum; 13 
hydrogel) occurred after one month. Eighteen were serious (7 platinum; 11 hydrogel). 
Details are provided in Table 7.  
Adverse events attributed to inflammation at any time after the procedure (including 
the first 30 days after treatment) occurred in 6 patients (4 platinum; 2 hydrogel). 
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Morbidity according to the modified Rankin scale and mortality is summarized in Table 
8. There were 16 deaths (3·6%; 3 platinum; 13 hydrogel; P= 0·011). Two deaths (both 
hydrogel) related to the initial SAH were reported previously. Two other deaths (one 
148 days after the procedure (platinum), the other at unknown time from unknown 
cause following treatment (hydrogel; the patient was lost to follow-up after 1-month) 
were not initially reported and have been adjudicated to be treatment-related delayed 
deaths. Two deaths 31 and 474 days after treatment were related to SAH at follow-up 
(hydrogel and platinum, respectively). Two deaths at 64 and 693 days were re-
treatment-related deaths (both hydrogel). Deaths unrelated to the aneurysm or to its 
treatment were reported in 8 patients (1 platinum; 7 hydrogel). Details are provided in 





A randomized comparison did not show any significant difference between patients in 
the hydrogel and platinum groups when assessing the primary outcome—a composite 
of major angiographic recurrence and clinical status. This was true for both large (PRET 
1) and recurrent aneurysm patients (PRET 2), and for each component of the primary 
outcome. Unsurprisingly in these high risk patients angiographic outcomes were inferior 
when compared to other coiling trials.16,17,22,23 Safety endpoints were similar for the 2 
groups, except for a greater number of deaths unrelated to the aneurysm or to 
treatment (7 versus 1) in the hydrogel group. A careful review of individual cases (online 
tbale 5) indicates that is probably a chance finding. 
There were more missing primary outcomes in the hydrogel group (n=7) than in the 
control group (n=2). Although some of these outcomes were missing for reasons 
unrelated to treatment, reasons are not known for all patients. Sensitivity analyses 
indicate that missing data would not have affected trial results. 
The median packing density of the hydrogel group was significantly higher than the one 
of the platinum group, but this did not translate into better long term angiographic 
results. The volumetric packing density calculation assumes full hydrogel expansion, 
which might not occur in vivo. Pre-planned analyses focusing on patients that have 
reached the ‘target hydrogel coiling strategy’ did not show better results than platinum 
coiling. There was a correlation between packing density and recurrences for each 
group studied separately, suggesting that packing density is better understood as an 
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index combining aneurysm characteristics (size, aspect ratio) and technical success of 
the coiling procedure (with any material) than an independent mechanistic mean to 
deliberately improve long term results of embolization, at least with hydrogel in large 
and recurrent aneurysms. 
Residual or recurrent aneurysms are signs that treatment may not be definitive. As 
expected, there were few hemorrhagic episodes (n= 4 or 0·9%) during the 18-month 
follow-up period, but 46 or 10·4% of patients were retreated, and re-treatments were 
planned for other 34 patients. 
Inflammatory problems have previously been a concern with the use of hydrogel.14,22,24-
27 In PRET adverse events that have been (rightly or wrongly) attributed to inflammation 
were transient, occurred rarely, and with equal frequency in both groups. 
Coiling of large and recurrent aneurysms proved to be safe.20 There were few delayed 
adverse events after 1 month. 
Treatment-related morbidity (4.0%) and mortality (0.7%) were relatively low for both 
groups considering these are higher risk groups. Unfortunately, the efficacy of coiling 
remains problematic, with poor long term outcomes in nearly half of patients. Major 
angiographic recurrence rates were higher than reported in other coiling studies8,28-30, 
but this was not unexpected for these high risk patients; indeed the trial hypothesized a 
50% recurrence rate for the control group. Similar 50% recurrence rates for both 




Whether patients treated with coiling should be followed to detect recurrences, and 
whether recurrences should be retreated are questions that cannot be answered by the 
present data. We can only point out that in spite of retreatment, three PRET-2 patients 
bled during follow-up; two others had progressive mass effect; residual or recurring 
aneurysms still occurred in more than 45% of patients, and re-retreatments were 
associated with serious adverse events in 3 patients. 
How patients with large or recurrent aneurysms should be managed remains an open 
question. In the landmark ISAT trial that has established coiling of ruptured aneurysms, 
as compared to clipping, clinical outcomes of patients with aneurysms > 10mm (n=155) 
were similar (RR 0·96; 0·65-1·42). Thus clipping, reputed but not proven, at least for 
unruptured aneurysms31 to be more durable than coiling, is a reasonable option for 
some of these patients although the long term follow-up ISAT data confirm  a low 
rebleed risk after de novo coiling and long term outcome superiority over clipping. REF 
LANCET 2015 Large ruptured aneurysm patients could be offered participation in the ISAT II 
trial.32 There is no randomized data for unruptured aneurysms, but a trial is ongoing.4 
Although meta-analyses of case series have reported improved angiographic results 
with stent-assisted coiling12 or flow diversion10 as compared to historical coiling 
controls, preliminary results from the FIAT trial have so far been below expectations.11 
Participation in these or other ongoing trials may be the best way to manage these high 
risk patients.33-36  
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The PRET trial had several limitations. Operators could not be blinded to coil type. This 
may have affected case selection, coil selection, and perhaps even modify the extent 
and completeness of the coiling procedure.  Aneurysm volumes were not directly 
measured but extrapolated from aneurysm dimensions, a method that typically 
overestimates volumes and under-estimates packing density. This is unlikely to have 
biased the comparison between groups. Recruitment was slowing down in the last years 
of enrolment, perhaps because treatment alternatives, such as flow diverters, were 
increasingly used for large and recurrent aneurysms. This may not affect generalizability 
of conclusions, equally disappointing for both groups. The PRET-2 sub-study was 
interrupted before the target number of patients was enrolled. Given the similarities in 
overall trial results, it is unlikely that a convincing difference between groups would 
have been shown had the trial reached its target. The relatively short 18-month follow-
up period was not completed by all patients, and the primary endpoint had to be 
imputed from the 6-month follow-up angiogram in 5·5% of patients. Short follow-up 
periods may not have captured all clinical consequences of recurrences, such as re-
treatments, along with the associated morbidity. Data monitoring was done on-line, 
with no local site visits to verify the data. Brain imaging studies were not imposed by 
protocol to verify the absence of asymptomatic complications. These perceived 




PRET Trial Collaborators  (need to update) 
The PRET trial collaborators are listed in the order that participating sites joined the trial, with 
the number of patients recruited given in parentheses. CHUM-Notre Dame Hospital, Montreal, 
Quebec, Canada: Principal Investigators (PIs), Jean Raymond, Alain Weill, and Daniel Roy; 
Coordinator, Ruby Klink (120). The Methodist Hospital, Houston, Texas: PIs, Richard Klucznik and 
Orlando Diaz; Coordinator, Marilyn Bautista (12). Kobe City Medical Center General Hospital, 
Kobe, Japan: PIs, Nobuyuki Sakai and Horotoshi Imamura (4). Medical University of South 
Carolina, Charleston, South Carolina: PIs, Aquilla Turk and Raymond Turner; Coordinator, Adrian 
Parker (26). State University of New York at Stony Brook University Medical Center, Stony Brook, 
New York: PI, Henry Woo; Coordinators, Susan Fiore and Dawn 8 Raymond Madigan (20). 
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